Health Archive » May, 2011

Health - May, 2011

216 articles

• FDA Probes Yaz, Others Over Blood Clot Risks
• Orthovita Shareholders Sue Over $316M Stryker Deal
• WHO Says Cellphone Radiation May Cause Cancer
• Pfizer Ends Patent War Over Generic Neurontin
• High Court Won't Hear Novartis Appeal Of Zometa Suit
• Following Follow-On Biologics Legislation
• 10 Tips To Ensure Your Trust Account Is Secure
• The Hidden Risks Of Being A Registered Agent
• Abbott Sues Boehringer Unit Over Generic Zemplar
• Galderma, Supernus Sue Impax Over Rosacea Treatment
• Ky. Jury Favors Rawlings In OT Class Action
• Somaxon Slaps Par With 2nd Suit Over Generic Silenor
• ARB Ruling Offers Broad View Of SOX Protections
• Exporter Admits To $1.3M FDA Fraud
• HP, Quest Sued Over Medical Records Software Patent
• The HEAT Is On, Chicago: Practical Tips To Prepare
• SG Sides Against Novo In Dispute Over Generics
• Attys' Collaboration Fight To Stay In Federal Court
• Medicaid Can Seek Money From Insurers: Mont. Court
• Judge Refuses To Toss Botox Marketing Class Action
• Fresenius Must Pay $83M For Medicare Overcharges
• Fed. Circ. To Rehear McKesson Joint Infringement Case
• Q&A With Crowell & Moring's Jennifer Romano
• Amylin Wins Restraining Order On Lilly Drug Sales
• Jury Sides With Novartis In Widow's Bone Drug Suit
• GSK, Pfizer, Others Targeted In DNA Patent Suit
• Considering Cross-Border M&A In The Middle East
• IP Lawyers Weigh In On Inequitable Conduct Ruling
• Fed. Circ. Tightens Inequitable Conduct Standards
• Sanofi Paid Doctors To Help Delay Lovenox Generic: Sens.
• Medtronic's Infuse Tied To Male Infertility Risks
• 34 Women Sue AstraZeneca Over Nexium Bone Risks
• Plaintiffs, Claims Added To $100M Bayer Sex Bias Suit
• AstraZeneca Adds Intellipharmaceutics To Seroquel Row
• Watson Expands Generics Biz With $562M Specifar Buy
• FDA Issues Class 1 Recall Of Beckman Blood Analyzer
• MAS-Alere Merger Still On Despite Roche Suit: 7th Circ.
• Adviser Gets 2 Years For Trading On Ex-UBS Banker's Tips
• Apotex Infringed Alcon's Eye Drop Patent: Judge
• White House Cracks Down On Misuse Of Federal Cash
• FTC Urges 3rd Circ. To Reverse Pay-For-Delay Ruling
• Fed. Circ. Revives Competition Claims In Latisse Suit
• Defining The Essential Health Benefits Package
• Applied Medical Hits Covidien With Seal Patent Suit
• After Failed Cephalon Bid, Valeant Buys Sanitas For $443M
• Philips Recalls Infant, Neonatal CO2 Devices
• Mayer Brown Reps Nestle In Diagnostics Co. Buy
• PSS Sues Over Poached Clients, Trade Secrets
• JPML Consolidates Depuy Hip Implant Suits in Texas
• Judicial Panel Consolidates Fosamax Femur Fracture Suits
• JPML Won't Separate La. Avandia Suit From MDL
• Lessons From Southwest Health Alliance
• Pa. Jury Slaps J&J Unit With $10M Motrin Verdict
• J&J Buys Russian Cold Drug Brands For $260M
• High Court Preemption Ruling Would Hit Branded Cos. Hard
• XenoPort Investors' Horizant Suit Tossed For Now
• Wash. Hospital Workers Sue Over Racial Discrimination
• 4th Circ. Returns W.Va. Pharmacy Suit To State Court
• Contractor Sues AIG Unit Over Defense Of $44M Suit
• Cephalon Granted TRO In Amrix Patent MDL
• Mylan Settles Kentucky Drug-Pricing Suit For $6.5M
• Pfizer Resubmits Thousands Of Adverse Chantix Reports
• Allergan Hits Lupin With 2nd Eye Drop Patent Suit
• Novartis Seeks To Nix Expert Testimony In Bone Drug MDL
• 9th Circ. Nixes Pharmacies' Pfizer-Wyeth Merger Suit
• FBI Seeks Unabomber DNA Over 1982 Tylenol Deaths
• US Mandates Health Insurance Rate Hike Reviews
• 7th Circ. Upholds Black Lung Benefits Act Amendment
• Genentech Sues Apotex Over Generic Valcyte
• FDA Urged To Pull Eisai's High-Dose Aricept
• Exela Didn't Infringe Alphagan IP: Fed. Circ.
• Abbott Wins IP Validity Ruling In Niaspan Suit
• SEC Probes Embattled CHS' Medicare Billing
• GAO Denies Protest Of $3B MetLife Dental Contract
• CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit
• Q&A With Morrison & Foerster's James Huston
• Takeda Goes Global With $13.7B Nycomed Deal
• WilmerHale Reps Thermo Fisher In $3.5B Phadia Buy
• FDA Pulls Avandia From US Pharmacies
• Firms, Experts Allowed To Stay In AndroGel MDL
• Nycomed, Glenmark Settle Feud Over Cutivate
• Revise Pain-Med Dosing Tips For Children: FDA Panels
• CVS, Rite Aid Strike Deal In OxyContin MDL
• The Limits Of Federal Rule Of Evidence 408
• Neurontin Judge Won't Certify 3rd-Party Bipolar Class
• FDA Warns Shire About Vyvanse Marketing
• NJ Class Suit Targets Bayer Probiotics Products
• Ex-Dallas Auditor Seeks Fast Win On Retaliation Claim
• Fla. Phlebotomist Sues Quest For OT Pay
• Ropes & Gray Reps InVentiv In PharmaNet Purchase
• 6th Circ. Upholds $101M Verdict Against HCP
• Schiff Nutrition Sued Over Dietary Supplement Claims
• Genzyme Sues Allergan Over Juvederm Gel IP
• Supreme Court Won't Hear Howmedica Polymer IP Appeal
• $100M Sex Bias Suit Barred By Contract: Cigna
• Ga. High Court Favors Vaccine Makers In Defect Case
• High Court Vacates Benefits Ruling For Cigna Class
• Amylin Sues Lilly Over Byetta Sales Plans
• Lupin Steps Up Fight With Mylan Over Generic Antara
• Policyholder Says John Alden Skimped On Health Coverage
• Fed. Circ. Upholds Rejection Of 2 Endo Opana Patents
• Lloyd's Doesn't Owe Bristol-Myers $11M For Theft: Suit
• NuAire Sues Wire Co. Over $1.8M Incubator Recall
• Life Partners, CEO, GC Could Face SEC Action
• CHS Faces Investor Suit Over Alleged Medicare Fraud
• Pfizer Expects To Pay $772M To End Hormone Drug Suits
• Cephalon's Amrix IP Invalid, Infringed: Judge
• I'm Glad High Court Nixed Cipro Cert Bid: FTC Commish
• 3rd Party Has Rights To Fraudster's Money: 7th Circ.
• Kinetic Unit Warned Over Breast Implant Marketing
• Executive Risk Must Cover Hospital Privacy Row: Judge
• US Seeks $1B From J&J Over Risperdal Marketing
• Advanced Generic Reloads In Antitrust Suit V. Drug Cos.
• Disgorgement: A Cure Worse Than The Disease?
• Possible Outcomes Of Stanford V. Roche
• GSK Beats ERISA Class Action Over Stock Price Drop
• 8th Circ. Won't Rehear KV Drug Recall Action
• Remedi Sues Zurich Over Medicare Suit Coverage
• Boston Scientific Wins $19.5M In Stent Patent Case
• Vets Have Due Process Right To Mental Care: 9th Circ.
• Cephalon Drops Nuvigil Patent Suit Against Teva
• Judge Snips DaVita Kickback Claims In FCA Suit
• FDA Asked To Probe 3M's MRSA Clinical Test Conduct
• Morgan Lewis Adds 2 McKenna Gov't Contract Pros
• Q&A With Sidley Austin's Thomas Hanrahan
• J&J Recalls HIV Drug Over Odor-Causing Chemical
• J&J Unit Sets Funds Aside For Risperdal Settlement
• Sanofi, Generics Failed To Report Ambien IP Deals: FTC
• FDA Orders 21 Hip Reserve Makers To Study Defects
• Whistleblower Told To Provide Docs In CHS Fraud Suit
• 4th Circ. Mulls Va. Standing In Health Care Law Fight
• Somaxon Sues Actavis Over Generic Silenor
• Aflac Can't Duck Class Action Over Child Premiums
• Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.
• FTC Orders Texas Doctors Group To Stop Rate Talks
• 10th Circ. Keeps Farmers Class Action In Federal Court
• 11th Circ. Trims Scrushy Conviction Based On Skilling
• Insurer Balks At Coverage For ProMedica Merger Suit
• High-Ranking DOJ Fraud Cop Heads To Mintz Levin
• Wilson Sonsini Lures IP Litigator From Katten Muchin
• GSK Atty Acquitted On All Counts In Obstruction Case
• How Health Care Is Being Challenged
• Becton Syringe Doesn't Infringe MBO's Patent: Judge
• Tenet Healthcare Spurns CHS' $4B Final Merger Offer
• DOD Services Contracts Outpace Other Growth
• Forest Labs Subpoenaed Over Hypertension Meds
• Quest Agrees To Settle Calif. Medicaid Suit For $241M
• US Can't Prove Wellbutrin Statements False: GSK Atty
• Health Care Industry Feels The HEAT
• Reissue Ruling A Boost To Patentees In Validity Fights
• Howrey Lessons: The Downside Of Contingent Fees
• Lilly Claims Zydus Broke Deal In Strattera Row
• Cleary Gottlieb Reps Alkermes In $960M Elan Unit Buy
• Mass. Constitution Protects Legal Immigrants: Court
• NLRB Targets Nurses' Union Over Unilateral CBA Text
• Enzo Can't Dodge Siemens' DNA Patent Priority Suit
• Canada High Court To Hear Teva's Viagra Patent Appeal
• Ivera Sues Excelsior Over Medical Valve Patent
• Synthes Investor Blasts $21B J&J Deal In Suit
• Wright Medical In Hot Seat Over $8M Kickbacks Settlement
• FTC Clears $338M Baxter-Prism Pharmaceuticals Deal
• Merck Unit Sues Sandoz Over Generic Noxafil
• Morgan Lewis Criminal Defense Pro Jumps To Dickstein
• Crowell Picks Up Hatch-Waxman Experts From Frommer
• J&J Units Again Sue To Block Impax's Generic Concerta
• Inspire Shareholders Try To Block $430M Merck Takeover
• Antitrust Guidance For ACOs: Still Evolving
• Sedgwick Hit With $200M Malpractice Suit
• Bayer Targets Lilly In False Ad Suit Over Pet Drugs
• Yaz Consumers Fail To Win Class Cert. In MDL Case
• Conn. AG, CVS Settle Expired Products Suit
• Medtronic Loses Bid To Take Lenox Suit To Arbitration
• Doctors Were Chastised For Wellbutrin Claims: GSK Exec
• 2nd Circ. Upholds $4M Fine In Insider Trading Suit
• P&G Can't Escape Align False Ad Action
• DR Systems Sues 16 Cos. Over Medical Imaging Patent
• Flamel Takes Lupin To Court Over Generic Coreg
• 4 Found Guilty In $5.2M Medicare Fraud Scheme
• Off-Label Use OK When Not Promoted, GSK Exec Says
• States Open Fight Over Health Care Law In 11th Circ.
• Former Cigna Atty Returns To Take On GC Role
• Merck Units To Pay $44M In Rebif Whistleblower Suit
• UnitedHealth Beats FCA Suit Over Hospital Payments
• Jazz Hits Roxane With Patent Suit Over Xyrem
• Barnes & Thornburg Lands Ex-Faegre & Benson Co-Chair
• Prescriptions For FCPA Pain
• Investor Tries To Stop LabCorp's $85M Orchid Buyout
• MetLife Intervenes In Protest Of $2B Dental Contract
• Actelion Vows To Appeal Jury Verdict In Asahi Fight
• GSK Scripted Response For Wellbutrin Probe, Atty Says
• Investors Sue J&J Board Over $78M In Settlements
• Pay-For-Delay Deals Hit 7-Year High In 2010: FTC
• 2nd Circ. Rejects Nurses Review Of Class Cert. Denial
• Takeda Sues Mylan Over Prevacid Patents
• Hatch Pushes To Repeal State Medicaid Mandate
• Blank Rome Snags Ex-Cozen Life Sciences Chair
• Wyeth Improperly Delayed Generic Effexor: Suit
• Miami Health Care Cos. Admit To $200M Medicare Fraud
• Senate Probes Medtronic Decision To Nix GPO Contracts
• US Regulators Clamp Down On Illegal STD Drugs
• Abbott Slaps Teva With Suit Over Generic AndroGel
• Pfizer, Eon Settle Neurontin Patent Claims
• Taro Sues Suven To Block Generic Lice Treatment
• Case Study: Wolfe V. McNeil-PPC
• FDA Gets Mylan Suit Over Generic Lipitor Tossed
• Impax Gets Amgen Vet As New GC
• AstraZeneca Ends Seroquel Case Against Biovail
• Santarus Defends Zegerid Patents In Fed. Circ.
• CHS Offers $4B Last-Ditch Bid For Tenet Healthcare
• FTC Clears Pfizer's $2.4B Capsugel Sale To KKR
• Grifols, FTC Ink Deal To Allow $3.4B Talecris Tie-Up
• Jones Day Lures M&A Pro From Edwards Angell
• Medicines Co. Sues Dr. Reddy's Over Generic Angiomax
• Addressing Multiforum Deal Litigation
• Killing The Golden Goose
• Teva Tops Valeant With $6.8B Cephalon Buy